electroCore, LLC (NASDAQ: ECOR) was founded in September 2005 and is headquartered in Basing Ridge, New Jersey, USA, with 64 full-time employees (5/21/2018). It is a commercial stage bio-electronic medicine company with a platform for non-invasive vagus nerve stimulation Therapies initially focused on neurology and rheumatology.
electroCore, LLC (ECOR):
electroCore’s gammaCore therapy has pharmacological effects on the peripheral and central nervous system, regulating neurotransmitter and immune function. gammaCore is a drug approved by the US Food and Drug Administration (FDA) for the treatment of acute pain associated with adult migraine and paroxysmal cluster headache.
In order to allow doctors to prescribe gammaCore and recommend it to patients in need, electroCore recently launched a product registration for episodic cluster headaches. electroCore has established a publicity base among experts in the field of headaches through the product registration agency. The company’s strategy is to launch commercial applications for migraine and paroxysmal cluster headaches in the third quarter of 2018.
According to electroCore’s clinical data, the company is pursuing an expanded program to prevent migraine, adolescent migraine and post-traumatic headache, and is undergoing clinical development to find potential new applications in the field of rheumatism, including Sjögren syndrome and rheumatoid arthritis.
gammaCore is the first FDA-approved prescription vagus nerve stimulation therapy to be administered in discrete doses using a proprietary, easy-to-use handheld delivery system. Several published studies have shown that VNS acts by regulating neurotransmitters and has measurable pharmacological effects similar to several classes of drugs, including the prescribed selective serotonin reuptake inhibitor, serotonin norepinephrine Reuptake inhibitors, GABA analogs, acetylcholinesterase inhibitors and triptans.
gammaCore activates the fibers in the vagus nerve that are related to neurotransmitter modulation therapy, mainly through the company’s proprietary high-frequency burst waveform, which safely and comfortably penetrates the skin and stimulates the target nerve fiber. Studies have also shown that VNS, including gammaCore, modulates the immune system to produce measurable effects on inflammatory cytokines, as measured in blood samples, comparable to drugs that inhibit these cytokines.
electroCore, LLC (ECOR) investment:
electroCore, LLC (NASDAQ:ECOR) submitted its IPO prospectus on 5/21/2018, and listed on NASDAQ on 6/21/2018 with an issue price of US$15.00. It issued 4,333,333 shares and raised US$65 million.